Works matching DE "DRUG therapy"


Results: 5000
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.

    Published in:
    OncoImmunology, 2013, v. 2, n. 2, p. e23079-1, doi. 10.4161/onci.23079
    By:
    • Pautier, Patricia;
    • Locher, Clara;
    • Robert, Caroline;
    • Deroussent, Alain;
    • Flament, Caroline;
    • Le Cesne, Axel;
    • Rey, Annie;
    • Bahleda, Ratislav;
    • Ribrag, Vincent;
    • Soria, Jean-Charles;
    • Vassal, Gilles;
    • Eggermont, Alexander;
    • Zitvogel, Laurence;
    • Chaput, Nathalie;
    • Paci, Angelo
    Publication type:
    Article
    11

    Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR<sup>+</sup> NK cell levels correlate with disease outcome.

    Published in:
    OncoImmunology, 2013, v. 2, n. 2, p. e23080-1, doi. 10.4161/onci.23080
    By:
    • Chaput, Nathalie;
    • Flament, Caroline;
    • Locher, Clara;
    • Desbois, Mélanie;
    • Rey, Annie;
    • Rusakiewicz, Sylvie;
    • Poirier-Colame, Vichnou;
    • Pautier, Patricia;
    • Le Cesne, Axel;
    • Soria, Jean-Charles;
    • Paci, Angelo;
    • Rosenzwajg, Michelle;
    • Klatzmann, David;
    • Eggermont, Alexander;
    • Robert, Caroline;
    • Zitvogel, Laurence
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37

    Neoadjuvant Chemotherapy.

    Published in:
    Breast Disease, 2004, v. 21, n. 1, p. 23, doi. 10.3233/BD-2004-21104
    By:
    • Green, Marjorie C.;
    • Esteva, Francisco J.;
    • Hortobagyi, Gabriel N.
    Publication type:
    Article
    38
    39
    40

    Selection Bias in Clinical Trials.

    Published in:
    Breast Disease, 2001, v. 14, n. 1, p. 31, doi. 10.3233/BD-2001-14105
    By:
    • Miller, Kathy D.;
    • Rahman, Zia U.;
    • Sledge Jr., George W.
    Publication type:
    Article
    41
    42
    43

    Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.

    Published in:
    OncoImmunology, 2012, v. 1, n. 4, p. 432, doi. 10.4161/onci.19545
    By:
    • Manuel, Manuarii;
    • Trédan, Olivier;
    • Bachelot, Thomas;
    • Clapisson, Gilles;
    • Courtier, Anais;
    • Parmentier, Gilles;
    • Rabeony, Tioka;
    • Grives, Audrey;
    • Perez, Solène;
    • Mouret, Jean-François;
    • Perol, David;
    • Chabaud, Sylvie;
    • Ray-Coquard, Isabelle;
    • Labidi-Galy, Intidhar;
    • Heudel, Pierre;
    • Pierga, Jean-Yves;
    • Caux, Christophe;
    • Blay, Jean-Yves;
    • Pasqual, Nicolas;
    • Ménétrier-Caux, Christine
    Publication type:
    Article
    44
    45
    46

    Trial watch: Chemotherapy with immunogenic cell death inducers.

    Published in:
    OncoImmunology, 2012, v. 1, n. 2, p. 179, doi. 10.4161/onci.1.2.19026
    By:
    • Vacchelli, Erika;
    • Galluzzi, Lorenzo;
    • Fridman, Wolf Hervé;
    • Galon, Jerome;
    • Sautès-Fridman, Catherine;
    • Tartour, Eric;
    • Zitvogel, Laurence;
    • Kroemer, Guido
    Publication type:
    Article
    47
    48
    49
    50